Using our proprietary SAMiRNA prodrug platform technology, Bioneer is currently advancing clinical development of pipeline programs for previously non-druggable targets,
including cancer, COPD, liver fibrosis, and antivirals,
internally with our research and development resources as well as through partnerships with major global pharmaceutical companies.
Survivin
- A member of the inhibitor of apoptosis (IAP) family
- Functions to inhibit caspase activation, leading to the inhibition of apoptosis
- Disruption of Survivin expression leads to decrease in tumour growth
- Expressed highly in most human tumors including breast and colon cancers
- But, completely absent in terminally differentiated cells, making Survivin an ideal target for cancer therapy
- Also expressed in circulating tumor cells (CTCs), which are associated with malignancies and metastasis
- Disruption of Survivin pathway treatment of metastasis and for prevention of tumor recurrence from various cancers